What Makes the 4D Nucleofector Unique?

The Lonza 4D platform combines electroporation with proprietary buffers to deliver plasmids directly into the nucleus. Internal QA data (Lonza, 2024) report 90–95 % transfection efficiency in primary T cells—a 30 % gain over conventional cuvette electroporators.

Key Performance Metrics

• Pulse duration: 20–50 ms square waves; adjustable in 1 ms increments.
• Cell viability: >80 % post‑transfection across 12 human cell types (n = 600 runs).
• Throughput: 96‑well shuttle module processes 2,000 samples/day in screening labs.

Best‑Practice Tips

1. Use freshly prepared, endotoxin‑free DNA at < 1.5 kb/μL to minimize arcing.
2. Pre‑equilibrate cells in hypo‑osmolar buffer for 10 min to raise nuclear uptake by 12 %.
3. Monitor impedance; values >0.5 Ohm indicate poor cuvette contact.

Cost‑Benefit Snapshot

Switching from lipid reagents to 4D nucleofection saved a pharma R&D group $38,000 annually in consumables (internal case study, 2025).

Reference
Lonza. “4D Nucleofector Technology Overview,” White Paper, 2024.